What is the efficacy of adding bevacizumab to platinum-based chemotherapy as first-line treatment of non–small cell lung cancer (NSCLC)?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

A 2012 systematic review and meta-analysis of randomized phase II/III trials concluded that the addition of bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC significantly prolonged overall and progression-free survival. The effects of bevacizumab on overall survival were significantly greater in patients with adenocarcinoma versus other histologies. No unexpected toxicity was observed. [178]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!